[{"address1": "828 Winter Street", "address2": "Suite 300", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "857 524 2466", "website": "https://xiliotx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rene  Russo BCPS, Pharm.D.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 875130, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Frankenfield", "age": 41, "title": "Chief Operating Officer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 704848, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Katarina  Luptakova M.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 591917, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin M. Brennan", "age": 53, "title": "Senior VP of Finance & Accounting", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uli  Bialucha Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott  Coleman Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.99, "open": 1.05, "dayLow": 1.035, "dayHigh": 1.4, "regularMarketPreviousClose": 0.99, "regularMarketOpen": 1.05, "regularMarketDayLow": 1.035, "regularMarketDayHigh": 1.4, "beta": -0.067, "forwardPE": -2.3620691, "volume": 3461352, "regularMarketVolume": 3461352, "averageVolume": 203870, "averageVolume10days": 513180, "averageDailyVolume10Day": 513180, "bid": 1.33, "ask": 1.43, "bidSize": 100, "askSize": 100, "marketCap": 60214924, "fiftyTwoWeekLow": 0.49, "fiftyTwoWeekHigh": 2.894, "priceToSalesTrailing12Months": 25.547274, "fiftyDayAverage": 0.83046, "twoHundredDayAverage": 0.898525, "currency": "USD", "enterpriseValue": -6045087, "floatShares": 22617512, "sharesOutstanding": 43952500, "sharesShort": 104746, "sharesShortPriorMonth": 14750, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0023999999, "heldPercentInsiders": 0.4093, "heldPercentInstitutions": 0.30224, "shortRatio": 0.76, "shortPercentOfFloat": 0.0029, "bookValue": 0.76, "priceToBook": 1.8026316, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -65531000, "trailingEps": -1.98, "forwardEps": -0.58, "enterpriseToRevenue": -2.565, "enterpriseToEbitda": 0.093, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "XLO", "underlyingSymbol": "XLO", "shortName": "Xilio Therapeutics, Inc.", "longName": "Xilio Therapeutics, Inc.", "firstTradeDateEpochUtc": 1634909400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a29df73e-2ef5-3eed-8f1d-9d3cdeb4d4fb", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.37, "targetHighPrice": 6.0, "targetLowPrice": 5.0, "targetMeanPrice": 5.5, "targetMedianPrice": 5.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 74949000, "totalCashPerShare": 1.705, "ebitda": -64907000, "totalDebt": 8689000, "quickRatio": 1.94, "currentRatio": 2.019, "totalRevenue": 2357000, "debtToEquity": 26.003, "revenuePerShare": 0.054, "returnOnAssets": -0.45755002, "returnOnEquity": -1.30031, "freeCashflow": -3613000, "operatingCashflow": -17345000, "grossMargins": 1.0, "operatingMargins": -6.22571, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]